Breaking News, Collaborations & Alliances

Evox, Icahn School of Medicine Partner to Advance Next-Gen Gene Therapy

Will work on developing exoAAV vectors as a novel gene delivery technology aimed at improving treatments for heart disease.

Evox Therapeutics Ltd., a exosome therapeutics company, entered into a research collaboration and option agreement with the Icahn School of Medicine at Mount Sinai in New York. The collaboration will work on developing exosome encapsulated AAV (exoAAV) vectors as a novel gene delivery technology aimed at improving treatments for heart disease. Evox and Icahn Mount Sinai are focused on tackling a long-standing challenge in cardiovascular medicine, namely the safe and effective delivery of gene...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters